“…BACKGROUND: HER2-low cancers are heterogeneous with different degrees of HER2 expression and hormone receptor (HR) status. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We found that zanubrutinib is a potential inhibitor of the HER2 signalling pathway, displaying an antiproliferative effect in HER2-positive BCa cell lines. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We established HER3‐and/or MET‐KO SW1116 cell lines, and HER3/MET‐double KO resulted in the inhibition of in vitro cell proliferation and in vivo tumor growth in nude mice by SW1116 cells. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…They include p53, p63, and HER2. This study was conducted on 88 patients suspected of urinary bladder carcinoma. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In this trial, T-DXd was associated with a substantial survival benefit among patients with hormone receptor-positive and hormone receptor-negative disease and low expression of HER2, a biomarker previously considered unactionable in this treatment setting. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This article is devoted to the study of the correlation between the emotional state of a person and the posture of his or her body in the sitting position. In order to carry out the study, we developed the first version of the hardware-software system based on a posturometric armchair, allowing the characteristics of the posture of a sitting person to be evaluated using strain gauges. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Central nervous system (CNS)-penetrating systemic therapies for patients with HER2-negative BrM are lacking; given CNS activity of trastuzumab deruxtecan, efficacy for patients with HER2-low BrM is of interest. …”
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10–20% of gastric cancers. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Human Epidermal Growth Factor Receptor-2 (HER2)-negative breast cancers (BCs) contain HER2-low and HER2-zero ones. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…[Image: see text] Sixteen chemically varied metabolites were isolated from the bulbs of Hippeastrum vittatum (L’Her.) Herb., including eight flavonoids [3′-methyl isoliquiritigenin (2), 7-hydroxyflavan (8), 7-hydroxyflavanone (9), 7-hydroxyflavan-3-ol (10), 7-methoxy-3′,4′-methylenedioxyflavan-3-ol (11), 7-hydroxy-3′,4′-methylenedioxy flavan (12), 2′,4′-dihydroxy-3′-methyl-3,4-methylenedioxychalcone (13), and isoliquiritigenin (14)], four acetophenones [2,6-dimethoxy-4-hydroxyacetophenone (3), 2,4-dihydroxyacetophenone (4), 2,4-dihydroxy-6-methoxy-3-methylacetophenone (6), and 2,4,6-trimethoxyacetophenone (7)], two alkaloids [lycorine (1) and narciprimine (15)], one phenol derivative [p-nitrophenol (5)], and one steroid [β-sitosterol 3-O-β-glucopyranoside (16)]. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…MATERIALS & METHODS: We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Cytokine storm induced by anti-human epidermal growth factor receptor-2 (HER2) therapies has not been reported. We report a patient with breast cancer treated with trastuzumab/pertuzumab who developed severe biventricular dysfunction and cardiogenic shock (CS) 6 months after starting double anti-HER2 therapy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The binding affinity of trastuzumab and pertuzumab to HER2 has been studied using both experimental and in silico methods. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…HER2 (Human Epidermal Growth Factor Receptor 2)-positive breast cancer is characterized by amplification of the HER2 gene and is associated with more aggressive tumor growth, increased risk of metastasis, and poorer prognosis when compared to other subtypes of breast cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Because of the phenomenal success of treatment with monoclonal antibodies and antibody‐drug conjugates targeting human epidermal growth factor receptor 2 (HER2), most patients with early‐stage HER2‐positive breast cancer (HER2+ BC) and some with limited metastatic diseases have been cured, and those who have not been cured have achieved significant improvements in overall survival, which has weakened the role of the TNM staging system in the prognosis of HER2+ BC today. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…One such mutation causes an increase in proteins named HER2 on the tumor cell surfaces. This article summarizes the evidence behind all of the different HER2-targeting therapies for uterine serous carcinoma and uterine carcinosarcoma. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Breast tumors overexpressing human epidermal growth factor receptor (HER2) confer intrinsic resistance to endocrine therapy (ET), and patients with HER2/ estrogen receptor-positive (HER2+/HR+) breast cancer (BCa) are less responsive to ET than HER2−/ER+. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Consequently, several anti-HER2 therapies have been developed, such as trastuzumab. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso